Molecular testing, including chromosomal microarray analysis, distinguishes between aggressive and indolent kidney cancer subtypes, aiding in accurate diagnosis. Accurate diagnosis is critical for ...
SurvivorNet on MSN
FDA approves new targeted drug for advanced bile duct cancer, highlighting need for comprehensive molecular testing
The FDA approved a new targeted therapy called Lyrfigtu (lirafugratinib) on September 23, 2026, for a specific type of bile ...
Molecular diagnostics are specialized tests doctors use to look at proteins, RNA, and DNA in and on cancer cells. When you have breast cancer, they show your doctors what’s unique about your tumor so ...
Comprehensive upfront biomarker testing, including RAS, BRAF, HER2, and MSI status, now anchors first-line treatment selection in metastatic colorectal cancer, though reflexive testing adoption still ...
New NCCN guidelines highlight how structured exercise and molecular profiling significantly reduce recurrence rates. Regular exercise is no longer just a recommendation for general health; it is now a ...
Camryn was diagnosed with a low-grade glioma at age two after her parents noticed a lazy eye. Sixteen years, 11 brain surgeries and over six years of chemotherapy treatment, Camryn is now ...
Testing the molecular profile of prostate tumours identifies which patients with advanced prostate cancer are more likely to benefit from a chemotherapy treatment called docetaxel and live longer, ...
When patients develop a narrowing or blockage in the bile ducts—the tubes connecting the liver, gallbladder and intestines—physicians must determine whether the cause is cancer or a benign condition.
This episode takes up the practical mechanics of molecular testing in community oncology, beginning with turnaround time. This episode takes up the practical mechanics of molecular testing in ...
Prioritize NGS, liquid biopsy, AI-driven interpretation and strategic partnerships to capitalize on precision oncology, companion diagnostics and early detection.Dublin, Oct. 13, 2026 (GLOBE NEWSWIRE) ...
First CNSide payer agreement to include CNSide’s new CSF Molecular Profile tests alongside tumor cell enumerationExpands CNSide contracted payer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results